Literature DB >> 21217180

Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination.

Jessica Leung1, Rafael Harpaz, Noelle-Angelique Molinari, Aisha Jumaan, Fangjun Zhou.   

Abstract

BACKGROUND: herpes zoster (HZ) is caused by reactivation of latent varicella zoster virus and is often associated with substantial pain and disability. Baseline incidence of HZ prior to introduction of HZ vaccine is not well described, and it is unclear whether introduction of the varicella vaccination program in 1995 has altered the epidemiology of HZ. We examined trends in the incidence of HZ and impact of varicella vaccination on HZ trends using a large medical claims database.
METHODS: medical claims data from the MarketScan databases were obtained for 1993-2006. We calculated HZ incidence using all persons with a first outpatient service associated with a 053.xx code (HZ ICD-9 code) as the numerator, and total MarketScan enrollment as the denominator; HZ incidence was stratified by age and sex. We used statewide varicella vaccination coverage in children aged 19-35 months to explore the impact of varicella vaccination on HZ incidence.
RESULTS: HZ incidence increased for the entire study period and for all age groups, with greater rates of increase 1993-1996 (P < .001). HZ rates were higher for females than males throughout the study period (P < .001) and for all age groups (P < .001). HZ incidence did not vary by state varicella vaccination coverage.
CONCLUSIONS: HZ incidence has been increasing from 1993-2006. We found no evidence to attribute the increase to the varicella vaccine program.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21217180     DOI: 10.1093/cid/ciq077

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  86 in total

1.  Varicella zoster virus transmission in the vaccine era: unmasking the role of herpes zoster.

Authors:  Karen C Bloch; James G Johnson
Journal:  J Infect Dis       Date:  2012-03-27       Impact factor: 5.226

Review 2.  Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective.

Authors:  Robert W Johnson; Marie-José Alvarez-Pasquin; Marc Bijl; Elisabetta Franco; Jacques Gaillat; João G Clara; Marc Labetoulle; Jean-Pierre Michel; Luigi Naldi; Luis S Sanmarti; Thomas Weinke
Journal:  Ther Adv Vaccines       Date:  2015-07

3.  Trends in Nationwide Herpes Zoster Emergency Department Utilization From 2006 to 2013.

Authors:  Erica D Dommasch; Cara J Joyce; Arash Mostaghimi
Journal:  JAMA Dermatol       Date:  2017-09-01       Impact factor: 10.282

4.  Increasing Incidence of Herpes Zoster Over a 60-year Period From a Population-based Study.

Authors:  Kosuke Kawai; Barbara P Yawn; Peter Wollan; Rafael Harpaz
Journal:  Clin Infect Dis       Date:  2016-05-08       Impact factor: 9.079

5.  The history and mystery of VZV in saliva.

Authors:  Anne A Gershon
Journal:  J Infect Dis       Date:  2011-09-15       Impact factor: 5.226

Review 6.  Successes and challenges in varicella vaccine.

Authors:  Orestis Papaloukas; Georgia Giannouli; Vassiliki Papaevangelou
Journal:  Ther Adv Vaccines       Date:  2014-03

7.  Long-term persistence of zoster vaccine efficacy.

Authors:  Vicki A Morrison; Gary R Johnson; Kenneth E Schmader; Myron J Levin; Jane H Zhang; David J Looney; Robert Betts; Larry Gelb; John C Guatelli; Ruth Harbecke; Connie Pachucki; Susan Keay; Barbara Menzies; Marie R Griffin; Carol A Kauffman; Adriana Marques; John Toney; Kathy Boardman; Shu-Chih Su; Xiaoming Li; Ivan S F Chan; Janie Parrino; Paula Annunziato; Michael N Oxman
Journal:  Clin Infect Dis       Date:  2014-11-20       Impact factor: 9.079

8.  Chronic medical conditions as risk factors for herpes zoster.

Authors:  Riduan M Joesoef; Rafael Harpaz; Jessica Leung; Stephanie R Bialek
Journal:  Mayo Clin Proc       Date:  2012-10       Impact factor: 7.616

9.  Sociodemographic characteristics and chronic medical conditions as risk factors for herpes zoster: a population-based study from primary care in Madrid (Spain).

Authors:  María D Esteban-Vasallo; M Felicitas Domínguez-Berjón; Ruth Gil-Prieto; Jenaro Astray-Mochales; Angel Gil de Miguel
Journal:  Hum Vaccin Immunother       Date:  2014-05-07       Impact factor: 3.452

10.  Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease.

Authors:  M D Long; C Martin; R S Sandler; M D Kappelman
Journal:  Aliment Pharmacol Ther       Date:  2012-12-13       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.